Basis of Presentation and Significant Accounting Policies - Narrative (Details)	1 Months Ended						3 Months Ended		9 Months Ended		88 Months Ended
	Apr. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Oct. 31, 2018	Sep. 30, 2018
Accumulated deficit							$ 248,962,791		$ 248,962,791		$ 248,962,791	$ 209,153,659
Net loss from continuing operations							11,206,263	$ 10,646,825	35,255,457	$ 24,543,695
Cash, cash equivalents and short term investments							6,200,000		6,200,000		6,200,000
Derivative warrant liability							0		$ 0		0
Number of operating segments | segment									1
Unrecognized tax benefit							1,500,000		$ 1,500,000		1,500,000
Revenue							723,126	58,861	2,146,804	290,259
Customer deposits							4,100,000		4,100,000		4,100,000
Land option agreements							500,000		500,000		500,000
Other liabilities							$ 1,000,000.0		$ 1,000,000.0		$ 1,000,000.0
Held for sale
Discontinued operation, period of continuing involvement after disposal									1 year
Elusys Therapeutics business
Discontinued operation, period of continuing involvement after disposal									1 year
Shattuck
License fee received						$ 50,000
Initial license fees received						50,000
Proceeds from milestone payment		$ 100,000
Pelican Therapeutics, Inc.
Ownership interest in subsidiary							85.00%		85.00%		85.00%	85.00%	85.00%	80.00%
Scorpius Therapeutics, Inc.
Ownership interest in subsidiary							94.00%		94.00%		94.00%	94.00%
Pelican Therapeutics, Inc. | Grant and contract revenue
Amount awarded from CPRIT grant									$ 15,200,000
Revenue	$ 1,500,000						$ 0	$ 100,000	$ 0	$ 300,000	$ 15,200,000
Remaining grant amount receivable	$ 1,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 1
Revenue					$ 1,800,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 2
Revenue				$ 6,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 3
Revenue			$ 5,400,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Maximum
Amount awarded from CPRIT grant						$ 15,200,000